Two separate research teams have found a “pause button” for CAR-T cell therapy, which may overcome a vexing and sometimes fatal side effect of the cancer immunotherapy. Specifically, they repurposed a small molecule drug, dasatinib, and found that it rapidly, precisely, and reversibly halts CAR-T function in mice — and the life-threatening inflammatory response called cytokine release syndrome (CRS).

Collaborators from Memorial Sloan Kettering Cancer Center in New York and the University of Würzburg in Germany published their work last week in Science Translational Medicine. A Stanford University group using the same drug, which is already approved to treat some leukemias, reported similar results in March in Blood Advances. Dr. Marco Ruella, scientific director of the lymphoma program of the Hospital of the University of Pennsylvania, said many researchers are working to characterize an off/on switch for CAR-T cells, which highlights the urgency of finding better ways to stave off CRS. 

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy